Patents by Inventor Jacques Roberge

Jacques Roberge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods for inhibiting ribosome inactivating proteins
    Patent number: 12427135
    Abstract: The disclosure provides in one aspect a method of treating, ameliorating, and/or preventing toxicity caused by a ribosome inactivating protein (RIP) in a subject. In certain embodiments, the method comprises administering to the subject a therapeutically effective amount of at least one compound of the disclosure.
    Type: Grant
    Filed: March 9, 2022
    Date of Patent: September 30, 2025
    Assignee: Rutgers, The State University of New Jersey
    Inventors: Nilgun E. Tumer, Xiao-Ping Li, Jacques Roberge, David Augeri, Bin Cao
  • CRK-LIKE (CRKL) ADAPTOR PROTEIN INHIBITORS AND METHODS OF MAKING AND USING THE SAME
    Publication number: 20250154180
    Abstract: Disclosed herein are embodiments of compounds that exhibit Crk-like protein inhibition. The compound embodiments can be used to suppress or prevent tumor cell growth and/or to inhibit a Crk-mediated signaling pathway. Methods of making and using the compound embodiments are disclosed herein.
    Type: Application
    Filed: February 1, 2023
    Publication date: May 15, 2025
    Applicant: Rutgers, The State University of New Jersey
    Inventors: Dongfang Liu, Xuening Wang, Jacques Roberge
  • FLAVONOID DERIVATIVES WITH GABAA RECEPTOR ACTIVITY AND METHODS OF USE
    Publication number: 20240398821
    Abstract: Provided herein are GABAAR positive modulator compounds of Formula I and methods for treatment of anxiety, distress and/or alcohol use disorder using these compounds. In certain embodiments, the compounds are stable and efficacious flavonoid derivatives that do not exhibit negative side effect(s) when administered in conjunction with alcohol consumption.
    Type: Application
    Filed: October 6, 2022
    Publication date: December 5, 2024
    Inventors: Eileen Carry, James E. Simon, Jacques Roberge
  • Crystalline form of benzylbenzene SGLT2 inhibitor
    Patent number: 10981942
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: November 25, 2019
    Date of Patent: April 20, 2021
    Assignee: THERACOS SUB, LLC
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Roberge
  • CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR
    Publication number: 20200239510
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Application
    Filed: November 25, 2019
    Publication date: July 30, 2020
    Inventors: Mengzhuang CAI, Qian LIU, Ge XU, Binhua LV, Brian SEED, Jacques ROBERGE
  • Crystalline form of benzylbenzene SGLT2 inhibitor
    Patent number: 10533032
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: January 14, 2020
    Assignee: THERACOS SUB, LLC
    Inventors: Mengzhuang Cai, Qian Liu, Ge Xu, Binhua Lv, Brian Seed, Jacques Roberge
  • Preparation of hydroxy-benzylbenzene derivatives
    Patent number: 10093616
    Abstract: Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.
    Type: Grant
    Filed: August 16, 2016
    Date of Patent: October 9, 2018
    Assignee: THERACOS SUB, LLC
    Inventors: Jacques Roberge, Carine Vaxelaire, Baohu Liu, Ge Xu, Jian Zhang, Xinxing Tang, Baihua Xu
  • CRYSTALLINE FORM OF BENZYLBENZENE SGLT2 INHIBITOR
    Publication number: 20180118773
    Abstract: Provided are crystalline forms of a compound having an inhibitory effect on sodium-dependent glucose cotransporter SGLT2. The invention also provides pharmaceutical compositions, methods of preparing the crystalline compound, and methods of using the crystalline compound, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT or SGLT2 inhibition.
    Type: Application
    Filed: November 6, 2017
    Publication date: May 3, 2018
    Inventors: Mengzhuang CAI, Qian LIU, Ge XU, Binhua LV, Brian SEED, Jacques ROBERGE
  • Process for the preparation of benzylbenzene SGLT2 inhibitors
    Patent number: 9725478
    Abstract: Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.
    Type: Grant
    Filed: November 19, 2015
    Date of Patent: August 8, 2017
    Assignee: Theracos Sub, LLC
    Inventors: Baihua Xu, Binhua Lv, Ge Xu, Brian Seed, Jacques Roberge
  • PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES
    Publication number: 20160355471
    Abstract: Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.
    Type: Application
    Filed: August 16, 2016
    Publication date: December 8, 2016
    Inventors: Jacques ROBERGE, Carine VAXELAIRE, Baohu LIU, Ge XU, Jian ZHANG, Xinxing TANG, Baihua XU
  • Preparation of hydroxy-benzylbenzene derivatives
    Patent number: 9464043
    Abstract: Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.
    Type: Grant
    Filed: October 10, 2014
    Date of Patent: October 11, 2016
    Assignee: THERACOS SUB, LLC
    Inventors: Jacques Roberge, Carine Vaxelaire, Baohu Liu, Ge Xu, Jian Zhang, Xinxing Tang, Baihua Xu
  • PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS
    Publication number: 20160207952
    Abstract: Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds.
    Type: Application
    Filed: November 19, 2015
    Publication date: July 21, 2016
    Inventors: Baihua Xu, Binhua Lv, Ge Xu, Brian Seed, Jacques Roberge
  • PREPARATION OF HYDROXY-BENZYLBENZENE DERIVATIVES
    Publication number: 20150210634
    Abstract: Methods for preparing intermediates of SGLT2 inhibitors are provided, including crystalline forms and methods of crystallizing intermediates.
    Type: Application
    Filed: October 10, 2014
    Publication date: July 30, 2015
    Inventors: Jacques Roberge, Carine Vaxelaire, Baohu Liu, Ge Xu, Jian Zhang, Xinxing Tang, Baihua Xu
  • Benzylbenzene derivatives and methods of use
    Patent number: 8575321
    Abstract: Provided are compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by SGLT inhibition.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: November 5, 2013
    Assignee: Theracos, Inc.
    Inventors: Yuanwei Chen, Huawei Cheng, Shengbin Li, Yuelin Wu, Yan Feng, Binhua Lv, Baihua Xu, Brian Seed, Michael Hadd, Yanli Song, Jiyan Du, Congna Wang, Jacques Roberge
  • HETEROCYCLIC CETP INHIBITORS
    Publication number: 20070135631
    Abstract: Compounds of formula Ia and Ib wherein A, B, C and R1 are described herein.
    Type: Application
    Filed: November 13, 2006
    Publication date: June 14, 2007
    Inventors: Mark Salvati, Heather Finlay, Bang-Chi Chen, Lalgudi Harikrishnan, Ji Jiang, James Johnson, Muthoni Kamau, R. Lawrence, Jianqing Li, John Lloyd, Michael Miller, Zulan Pi, Jennifer Qiao, Richard Rampulla, Jacques Roberge, Tammy Wang, Yufeng Wang, Wu Yang
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20060264459
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: February 15, 2006
    Publication date: November 23, 2006
    Inventors: Mark Salvati, James Balog, Dacia Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh Patel, Ronald Hanson, Toomas Mitt, Jacques Roberge, James Corte, Steven Spergel, Richard Rampulla, Raj Misra, Hai-Yun Xiao
  • Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20060223832
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: August 12, 2004
    Publication date: October 5, 2006
    Inventors: Mark Salvati, James Balog, Dacia Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh Patel, Ronald Hanson, Toomas Mitt, Jacques Roberge, James Corte, Steven Spergel, Richard Rampulla, Raj Misra, Hai-Yun Xiao
  • Fused Heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
    Publication number: 20050272799
    Abstract: Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.
    Type: Application
    Filed: July 7, 2005
    Publication date: December 8, 2005
    Inventors: Mark Salvati, James Balog, Dacia Pickering, Soren Giese, Aberra Fura, Wenying Li, Ramesh Patel, Ronald Hanson, Toomas Mitt, Jacques Roberge, James Corte, Steven Spergel, Richard Rampulla, Raj Misra, Hai-Yun Xiao
  • Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
    Publication number: 20050267119
    Abstract: The present invention provides novel pyridyl or phenyl ureas and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Application
    Filed: May 11, 2005
    Publication date: December 1, 2005
    Inventors: Hannguang Chao, Huji Tuerdi, Timothy Herpin, Jacques Roberge, Yalei Liu, R. Lawrence, Robert Rehfuss, Charles Clark, Jennifer Qiao, Timur Gungor, Patrick Lam, Tammy Wang, Rejean Ruel, Alexandre L'Heureux, Carl Thibeault, Gilles Bouthillier, Dora Schnur
  • Amino-benzazoles as P2Y1 receptor inhibitors
    Publication number: 20050203146
    Abstract: The present invention provides novel amino-benzazoles and analogues thereof, which are selective inhibitors of the human P2Y1 receptor. The invention also provides for various pharmaceutical compositions of the same and methods for treating diseases responsive to modulation of P2Y1 receptor activity.
    Type: Application
    Filed: January 19, 2005
    Publication date: September 15, 2005
    Inventors: Timothy Herpin, George Morton, Robert Rehfuss, R. Lawrence, Michael Poss, Jacques Roberge, Timur Gungor